Introduction

Positron emission tomography (PET) with Ga-Prostate Specific Membrane Antigen (PSMA) is a new imagiological technique to stage patients with prostate cancer. _x000D_ We aim to present the results of our preliminary analysis of 101 consecutive patients who performed this exam in our institution, exploring its utility in primary staging and re-staging after primary local treatment and its influence on clinical decision making. _x000D_

Methods

From October 2015 to September 2016, 101 consecutive patients underwent Ga-PSMA PET/CT to stage patients before primary local treatment or, to detect recurrent or progressive disease after local treatment with curative intent in case of biochemical failure or persisting high PSA levels. _x000D_ All the exams were performed and read by nuclear medicine doctors. After the exam, in a multidisciplinary meeting, urologists, oncologists and radioncologists decided the treatment strategy in management of the patient. The exam was judged "influent" if its results, positive or negative, supported or determined a modification in clinical strategy._x000D_ _x000D_ _x000D_

Results

Patients´characteristics are presented in table 1. _x000D_ Globally, Ga-PSMA PET/CT detected at least one hypermetabolic lesion in 66/101 patients (65.3%).Detection rates were 23.3%, 33.3%, %, 41.2% and 91.1% for PSA-levels between 0.2-0.5, 0.5-1, >1-2 and >2, respectively. _x000D_ Before the PET PSMA, 19 patients performed a pelvic MRI, 16 patients performed a bone scintigraphy, 7 patients a CT and 5 patients a PET-Choline exam. _x000D_ The concordance rate for positive results of Ga-PSMA PET/CT was 80% for pelvic MRI, 57.2% for bone scintigraphy, 66.7% for CT and 25% for PET-Choline exam. _x000D_ The main treatment influences of Ga-PSMA PET/CT on clinical decisions are presented in graphic 1. Decision-making was critically affected by PET-PSMA results in 81/101 (81.1%) patients.

Conclusions

We report our preliminary experience with Ga-PSMA PET/CT in primary staging and re-staging after primary local treatment. This exam influenced our clinical decisions in 81.2% of patients.

Funding

None